The Challenges of First-in-Human Stem Cell Clinical Trials:What Does This Mean for Ethics and Institutional Review Boards? by Barker, Roger A. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Challenges of First-in-Human Stem Cell Clinical Trials
Citation for published version:
Barker, RA, Carpenter, MK, Forbes, S, Goldman, SA, Jamieson, C, Murry, CE, Takahashi, J & Weir, G
2018, 'The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and
Institutional Review Boards?', Stem Cell Reports, vol. 10, no. 5, pp. 1429-1431.
https://doi.org/10.1016/j.stemcr.2018.04.010
Digital Object Identifier (DOI):
10.1016/j.stemcr.2018.04.010
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Stem Cell Reports
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Stem Cell Reports
PerspectiveThe Challenges of First-in-Human Stem Cell Clinical Trials: What Does This
Mean for Ethics and Institutional Review Boards?
Roger A. Barker,1,* Melissa K. Carpenter,2 Stuart Forbes,3 Steven A. Goldman,4,5 Catriona Jamieson,6
Charles E. Murry,7 Jun Takahashi,8 and Gordon Weir9
1Cambridge University, Cambridge Centre for Brain Repair, E.D. Adrian Building, Cambridge CB2 2PY, UK
2Carpenter Group Consulting, Inc., Seattle, WA, USA
3Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
4University of Rochester Medical Center, Rochester, USA
5Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
6University of California, San Diego, Alpha Stem Cell Clinic, San Diego, CA, USA
7University of Washington, Institute for Stem Cell and Regenerative Medicine, Seattle, WA 98109, USA
8Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
9Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA
*Correspondence: rab46@cam.ac.uk
https://doi.org/10.1016/j.stemcr.2018.04.010Stem cell-based clinical interventions are increasingly advancing
through preclinical testing and approaching clinical trials. The
complexity and diversity of these approaches, and the confusion
created by unproven and untested stem cell-based ‘‘therapies,’’
create a growing need for a more comprehensive review of these
early-stage human trials to ensure they place the patients at mini-
mal risk of adverse events but are also based on solid evidence of
preclinical efficacy with a clear scientific rationale for that effect.
To address this issue and supplement the independent review pro-
cess, especially that of the ethics and institutional review boards
who may not be experts in stem cell biology, the International
Society for Stem Cell Research (ISSCR) has developed a set of
practical questions to cover the major issues for which clear evi-
dence-based answers need to be obtained before approving a
stem cell-based trial.
In recent years, the number of clinical trials and range of
medical conditions being tested with stem cell-derived in-
terventions has expanded. The complexity and diversity
of these putative therapies, and their use in early-stage hu-
man trials, pose unique review challenges relative to those
required for pharmacological agents, which includes the
delivery of the therapy and the possible mode of function.
Unfortunately, the field has become increasingly
confounded by the desire to rapidly move some stem cell-
derived interventions to the clinic without sufficient scien-
tific rationale to support this approach, including growing
numbers of direct-to-consumer, incompletely tested, or
even untested, ‘‘cell therapies.’’ The latter, untested, puta-
tive therapies are often described as trials even though
the patient is required to pay for the experimental treat-
ment, an atypical approach that raises ethical concerns.
In addition, these ‘‘trials’’ are often registered on a clinical
trials website, such as clinicaltrials.gov, a common tactic
to convey legitimacy, even though simply being listed on
such sites offers no guarantees about the level of scientific
scrutiny that they have undergone. Consequently, institu-
tional review and ethics boards, physicians, scientists, and
especially patients, struggle to understand which of theseStem Cell
This is an open access article under the Cinterventions has sufficient merit to justify clinical evalua-
tion. By their very nature, cell-based interventions require
more comprehensive evaluation to ensure they have a
justified level of risk for the recipient, are based on solid pre-
clinical evidence of efficacy, and a clear scientific rationale
for that effect. This call for a greater emphasis on preclinical
data and rationale has been echoed by others for early
human trials (Kimmelman and Federico, 2017). This need
for a comprehensive, independent review is likely to
becomemore of an issue as the number of trials and condi-
tions that could be treated with stem cell-derived interven-
tions increases. Indeed, the volume of trials could dramat-
ically expand if, andwhen, regulatory agencies require that
direct-to-consumer interventions undergo a formal regula-
tory review. This welcome change would further increase
the need for ethics and institutional review boards to be
highly engaged and informed.
Therefore, it has become imperative to improve on the
evaluation of stem cell therapies, especially in first-in-
human studies, to distinguish between:
(1) Trials with justified merit and potential that are sup-
ported by strong scientific rationale; and
(2) Trials that do not have adequate preclinical safety
and efficacy testing and may therefore endanger pa-
tients and jeopardize the whole field of regenerative
medicine.
One way to enhance this process is to more fully engage
an independent ethics or institutional review board. These
key stakeholders need not be experts in stem cell biology to
make reasonable judgments about whether the preclinical
evidence justifies a clinical trial and/or whether such an
approved trial is appropriate to undertake at their institu-
tion(s). We submit that knowing a few basic facts about
stem cells, understanding fundamentals of preclinical
testing and clinical trial design, and good common sense
are sufficient. Toward that end, the ISSCR has developedReports j Vol. 10 j 1429–1431 j May 8, 2018 j ª 2018 The Authors. 1429
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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points of which are highlighted below.
The first consideration is whether the condition to be
treated is a disease of cellular deficiency. These are the dis-
eases for which stem cell-derived interventions have the
most logical application. In this context, stem cells
have two general mechanisms of action: direct integra-
tion to replace the damaged tissue (‘‘cellular replace-
ment’’), and indirect signaling to host tissues (‘‘paracrine
repair’’). To regenerate the tissue through cellular replace-
ment, stem cell derivatives must engraft in the tissue and
survive long term. Consequently, this modality requires
long-term monitoring of the patient. In paracrine repair,
the cells are typically delivered into systemic compart-
ments, such as the circulation or CSF, as they likely
work via transient signaling mechanisms. In this case,
the mechanism of action is typically less well defined
but can include reducing inflammation and scarring in
addition to promoting cell survival, or proliferation of
endogenous cells, and/or angiogenesis. Therapies that
cannot provide a clear mechanistic basis or reasonable
rationale, and that lack preclinical evidence of efficacy,
proof of concept, and safety, are unlikely to be ready for
clinical trials.
In addition to how the cells are thought towork and their
mode of delivery, the immunological relationship between
the transplanted cells and the patient is important. Inmost
cases the intervention involves allogeneic cells and so im-
mune suppression may be needed to prevent rejection or,
in the case of hematopoietic cell transplantation, immune
cells in the graft from attacking host tissues, as in graft-
versus-host disease. Grafts in the CNS and eye may be an
exception, as immune surveillance is restricted at these
sites; yet even then, some form of immunosuppression
may be needed, at least in the short term. The risks of
immunosuppression thus need to be considered before
trial approval or enrollment.
Once the general mechanism of action is understood
(cell replacement or paracrine repair), stem cell-based
clinical trials should largely follow the precedents already
established for the evaluation of small molecules, bio-
logics, and human tissues. Preclinical studies should
demonstrate safety and efficacy profiles that suggest
improvement over the standard of care. Cell production
needs to take place in facilities that follow current Good
Manufacturing Practices, with stringent quality control
for reagents and well-defined product release and potency
assays. Phase 1 trials should begin cautiously, e.g., with
dose-escalation protocols and phased enrollments to
allow complications to be identified with the fewest
possible patients. The design of these early trials will
need to balance the safety and efficacy profiles of the
stem cell therapy, while assessing the risk tolerance of1430 Stem Cell Reports j Vol. 10 j 1429–1431 j May 8, 2018specific patient populations. These trials should be prop-
erly funded (and not by the patients themselves), focus
on tolerability and feasibility, while establishing end-
points to be used in later safety and efficacy trials.
When treating solid organs such as the heart or brain,
delivery of the cells is a key feature and consideration.
Delivery systems such as the use of an intravascular
catheter or surgical injection may be required and need
to be evaluated during preclinical and clinical testing in
concert with the cell product, as they both can influence
the safety and efficacy profile of the therapeutic
tested. Such considerations also need to be undertaken
when the stem cell-derived intervention is combined
with other emerging technologies, e.g., gene therapy,
which brings with it its own regulatory issues and
concerns.
While helpful guidelines have been developed for the
clinical translation of stem cell-based interventions, they
broadly cover fundamental ethical aspects of stem cell ther-
apies (Daley et al., 2016). Yet for those having to make
decisions at the local level, such as ethics and institutional
review boards, a more succinct and directed document,
such as a simple questionnaire, might be more useful for
evaluating new cell therapy treatments and trials. These
questions should cover the major issues for which clear ev-
idence-based answers need to be obtained. This approach
has been developed by a group of physicians and regulators
working with the International Society for Stem Cell
Research (ISSCR). The document, ‘‘StemCell-Based Clinical
Trials: Practical Advice for Physicians and Ethics/
Institutional Review Boards’’ (http://www.isscr.org/docs/
default-source/clinical-resources/isscr-stem-cell-based-clnical-
trials-practical-advice_final_23jan2018.pdf?sfvrsn=2) pro-
vides a framework of questions that can engage and
empower the key stakeholders involved with the transla-
tion of therapies to patients.
The questionnaire is designed to provide practical advice
that addresses relevant issues as part of a broader review
process. By adopting such a review, those having to make
decisions on the potential benefits and safety of any pro-
posed stem cell-derived intervention will be able to ascer-
tain whether there is sufficient support for moving the
cell product to a clinical trial, and whether the underlying
science and clinical endpoints are reasonable for the pa-
tient population and the stage of therapeutic development.
To further support those overseeing the authorization of
these trials, additional resources will need to be provided.
These may include providing access to experts with
whom these issues can be discussed; possibly through es-
tablishing a national registry of such individuals, ideally
vetted through some already existing agency such as the
ISSCR or other reputable organizations. In addition, the
sponsor has a responsibility to provide answers to these
Stem Cell Reports
Perspectivequestions. While there are significant challenges to estab-
lishing such a resource and no immediate mechanism to
do so, collectively, this process would support the review
process but not prohibitively slow it, allowing trials to pro-
ceed at a speed dictated by the science. This will hopefully
protect the patients as well as this nascent field, while
allowing novel regenerative medicine products that have
the potential to transform lives to reach the clinic.REFERENCES
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